Trials / Completed
CompletedNCT03915067
BOTOX® for the Treatment of Platysma Prominence
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BOTOX® purified neurotoxin complex | BOTOX® superficial intramuscular injections. |
| DRUG | Placebo | Placebo injections. |
Timeline
- Start date
- 2019-04-23
- Primary completion
- 2020-04-16
- Completion
- 2020-04-16
- First posted
- 2019-04-16
- Last updated
- 2023-05-03
- Results posted
- 2023-05-03
Locations
12 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03915067. Inclusion in this directory is not an endorsement.